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Abstract
Background: Adverse cardiorespiratory events including apnea, bradycardia, and desaturations have
been described following administration of the first diphtheria-tetanus-pertussis-inactivated polio-
Haemophilus influenzae type B (DTP-IPV-Hib) immunization to preterm infants. The effect of the recent
substitution of acellular pertussis vaccine for whole cell pertussis vaccine on the frequency of these events
requires further study.
Methods: Infants with gestational age of ≤ 32 weeks who received their first DTP-IPV-Hib immunization
prior to discharge from two Edmonton Neonatal Intensive Care Units January 1, 1996 to November 30,
2000 were eligible for the study. Each immunized infant was matched by gestational age to one control
infant. The number of episodes of apnea, bradycardia, and/or desaturations (ABD) and the treatment
required for these episodes in the 72 hours prior to and 72 hours post-immunization (for the immunized
cohort) or at the same post-natal age (for controls) was recorded.
Results: Thirty-four infants who received DTP-IPV-Hib with whole cell pertussis vaccine, 90 infants who
received DTP-IPV-Hib with acellular pertussis vaccine, and 124 control infants were entered in the study.
Fifty-six immunized infants (45.1%) and 36 control infants (29.0%) had a resurgence of or increased ABD
in the 72 hours post-immunization in the immunized infants and at the same post-natal age in the controls
with an adjusted odds ratio for immunized infants of 2.41 (95% CI 1.29,4.51) as compared to control
infants. The incidence of an increase in adverse cardiorespiratory events post-immunization was the same
in infants receiving whole cell or acellular pertussis vaccine (44.1% versus 45.6%). Eighteen immunized
infants (14.5%) and 51 control infants (41.1%) had a reduction in ABD in the 72 hours post- immunization
or at the equivalent postnatal age in controls for an odds ratio of 0.175 (95%CI 0.08, 0.39). The need for
therapy of ABD in the immunized infants was not statistically different from the control infants. Lower
weight at the time of immunization was a risk factor for a resurgence of or increased ABD post-
immunization. Birth weight, gestational age, postnatal age or sex were not risk factors.
Conclusion: There is an increase in adverse cardiorespiratory events following the first dose of DTP-IPV-
Hib in preterm infants. Lower current weight was identified as a risk factor, with the risk being equivalent
for whole cell versus acellular pertussis vaccine. Although most of these events are of limited clinical
significance, cardiorespiratory monitoring of infants who are sufficiently preterm that they are receiving
their first immunization prior to hospital discharge should be considered for 72 hours post-immunization.
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Background
The current recommendation is to administer the first
routine immunization to preterm infants at the usual
chronological age of 8 weeks as the immunologic
response to vaccines at that age is almost equivalent to
that of term infants [1]. However, in multiple previous
studies, a 7 to 47% incidence of adverse cardiorespiratory
events including apnea, bradycardia, and/or desaturation
(ABD) has been reported following the first diphtheria-
tetanus-pertussis-inactivated polio-Haemophilus influenzae
type B (DTP-IPV-Hib) immunization of preterm infants
[2-10], with the most common theory being that these
events are precipitated by the whole cell pertussis compo-
nent of the vaccine [3]. Previous studies used infants as
their own controls, comparing events prior to and follow-
ing immunization. Birth weight, current weight, gesta-
tional age, and postnatal age have been studied as
potential risk factors for ABD with inconclusive results [4-
7,9,10].
A retrospective stratified cohort study was completed to
determine the frequency of adverse cardiorespiratory
events among premature infants following their first
immunization with DTP-IPV-Hib vaccine and to compare
the frequency of events following whole cell versus acellu-
lar pertussis vaccines. A further objective was to study pos-
sible risk factors for these adverse events.
Methods
Approval from the Health Research Ethics Board of the
University of Alberta was obtained for conducting this
study.
Patients
Infants with a gestational age of ≤ 32 weeks who received
their first DTP-IPV-Hib immunization prior to discharge
from two Neonatal Intensive Care Units (NICUs) at the
University of Alberta and Royal Alexandra Hospitals in
Edmonton, Alberta January 1, 1996 to November 30,
2000 were eligible for the study. A public health nurse vis-
its each NICU on a frequent basis and administers immu-
nizations to all infants who have reached 8 weeks of age,
assuming the attending physician identifies no contrain-
dication. Compliance with this intervention is excellent
with almost all infants discharged after 8 weeks of age
having received DTP-IPV-Hib. Each immunized infant
was then matched by gestational age to one control
selected from infants not yet discharged from NICU at an
equivalent chronologic age (some of whom had already
been immunized) during the 5-year study period by using
a random numbers table. The study date for controls was
equivalent to the postnatal age at time of immunization
of the matched immunized infant, with the date being
adjusted up to seven days in either direction to avoid the
control's own immunization, discharge, septic work up
(as infants unlikely to be immunized within seven days of
a septic work) or surgical procedure. Infants could be
entered in the study once as a control and once as an
immunized infant, spanning different dates each time.
Immunized infants and controls were excluded if they
were not on a cardiorespiratory monitor in the NICU for
the entire observation period, they were still ventilated,
there was concurrent administration of other vaccines, or
documentation of case notes was inadequate.
Definition of adverse cardiorespiratory events
The frequency of ABD was recorded in two observation
periods for each infant. For immunized infants, observa-
tion period #1 was the 72 hours pre-immunization and
observation period #2 was the 72 hours post-immuniza-
tion. For controls, observation period #1 was the 72 hours
prior to the date that corresponded to the equivalent age
at which the infant they were matched to was immunized
and observation period #2 was that date and the 48 hours
following that date. ABD were detected by cardiorespira-
tory monitors or by observation and recorded by nurses
caring for the infants. Apnea was defined as cessation of
respiration for 20 seconds or more. Bradycardia was
defined as a heart rate less than 100 beats per minute for
20 seconds or more. Desaturation was defined as oxygen
saturation ≤ 85%. An increase in adverse cardiorespiratory
event was defined as: 1) a resurgence of ABD as indicated
by greater than one ABD within observation period #2
with no ABD during observation period #1, or 2)
increased ABD as indicated by a 25% increase in the
number of ABD events within observation period #2 ver-
sus observation period #1. A reduction in adverse cardi-
orespiratory events was defined as: 1) resolution of ABD
as indicated by greater than one ABD event in observation
period #1 with none in observation period #2 or 2)
decreased ABD as indicated by a 25% decrease in ABD
events within observation period #2 versus observation
period #1.
Data collection
Birth weight, current weight, gestational age, sex, and the-
ophylline or doxapram use were recorded for immunized
infants and for controls, and the postnatal age at the time
of immunization and the vaccine type were recorded for
immunized infants. The number of episodes of ABD and
the treatment required for these events in observation
periods #1 and #2 were recorded for immunized infants
and for controls.
Statistical analysis
Data were analyzed using Stata. Cellular and acellular vac-
cines were compared by using Chi-square. A p < 0.05 was
considered statistically significant. Odds ratios were calcu-
lated using conditional logistic regression with the
dependent variable being either (a) an increase in adverseBMC Pediatrics 2006, 6:20 http://www.biomedcentral.com/1471-2431/6/20
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cardiorespiratory events or (b) a decrease in adverse cardi-
orespiratory events and the independent variable being
immunization. Differences were considered statistically
significant if the 95% confidence interval of the odds ratio
did not include the value one.
Results
Patients
One hundred ninety-two infants received their first DTP-
IPV-Hib immunization in NICU during the study period.
DTP-IPV-Hib with whole cell pertussis vaccine was used
prior to July 1, 1997 and DTP-IPV-Hib with acellular per-
tussis vaccine was used starting on this date. Sixty infants
had exclusion criteria and a further eight immunized
infants had to be excluded as an appropriate control
infant could not be identified.
Patient characteristics
One hundred twenty-four immunized infants and 124
controls were evaluated. The study date for controls was
adjusted up to seven days in either direction to avoid the
control's own immunization (n = 35), discharge (n = 10),
septic work up (n = 9), or surgical procedure (n = 1). There
was no statistical difference between the immunized
infants and controls in birth weight, current weight, gesta-
tional age, postnatal age or sex (Table 1). The mean birth
weight of immunized infants was 893 ± 236 grams (range
110–1730 grams), the mean current weight was 2056 ±
510 grams (range 1049–3220 grams), the mean gesta-
tional age was 26.5 ± 1.7 weeks (range 23–31 weeks), and
58% were male. The postnatal age of the infants at immu-
nization was < 70 days (n = 66), 70 to 100 days (n = 50),
101 to 129 days (n = 7) and > 120 days (n = 1) for a mean
age of 74 ± 14 days (range 58–125 days). Thirty-four
infants received DTP-IPV-Hib with whole cell pertussis
vaccine and 90 received DTP-IPV-Hib with acellular per-
tussis vaccine.
Incidence of adverse cardiorespiratory events
Fifty-six (45.1%) of the 124 infants who received their
first DTP-IPV-Hib and 36 (29.0%) of the 124 control
infants had an increase in adverse cardiorespiratory events
during observation period #2 (Table 2). There was a statis-
tically significant difference in the incidence of increase in
adverse cardiorespiratory events between immunized
infants and controls with an adjusted odds ratio for
immunized infants of 2.41 (95% CI 1.3, 4.5). Fifteen of
the 34 infants (44.1%) who received DTP-IPV-Hib with
whole cell pertussis vaccine had an increase in adverse car-
diorespiratory events post-immunization, as compared to
41 of the 90 infants (45.6%) who received DTP-IPV-Hib
with acellular pertussis vaccine (χ2 0.021; p = 0.89). Eight-
een (14.5%) of the 124 infants who received their first
DTP-IPV-Hib had a reduction in cardiorespiratory events
in observation period #2 compared to 51 (41.1%) of the
124 control infants (odds ratio 0.175; 95% CI 0.08, 0.39).
Of the 56 immunized infants with adverse cardiorespira-
tory events, 9 infants (16.1%) had increased oxygen
requirements and/or required initiation of continuous
positive airway pressure (CPAP) and 9 infants (16.1%)
required an increased theophylline dose. A 26-week gesta-
tion male infant who received acellular pertussis vaccine
required mechanical ventilation on the third day post-
immunization as he had a 36% increase in apneas post-
immunization that persisted despite initiation of CPAP
and theophylline. The need for therapy of adverse cardi-
orespiratory events in the immunized infants was not sta-
tistically different from the control group where 6 infants
(16.6%) had increased oxygen requirements and/or
required initiation of CPAP and 7 infants (19.4%)
required an increased theophylline dose.
Lower weight at the time of immunization was a risk fac-
tor for an increase in adverse cardiorespiratory events,
with the odds ratio per 100 gram increase in weight being
0.83 (95% CI 0.72, 0.96). There was no statistically signif-
icant difference in birth weight, gestational age, postnatal
age or sex in infants with and without an increase in
adverse cardiorespiratory events post-immunization.
Discussion
Previous studies have identified a possible increase in the
frequency of adverse cardiorespiratory events following
the first DTP-IPV-Hib immunization in preterm infants
[2-10]. Our study was the first to use a control group and
confirmed that in infants ≤ 32 weeks gestation, almost
half of infants had an increase of adverse cardiorespiratory
events in the 72 hours post-immunization which was sta-
tistically significantly higher than in the control group.
Table 1: Comparison of preterm infants receiving their first DTP-IPV-Hib immunization to control infants.
Immunized infants (n = 124) Controls (n = 124)
Birth weight (grams) 893 (range 110–1730) 892 (range 110–1840)
Weight at immunization (grams) 2056 (range 1049–3220) 2085 (range 1054–3500)
Gestational age (weeks) 26 (range 23–31) 26 (range 23–32)
Postnatal age at immunization (days) 74 (range 58–125) 74 (range 56–120)
Male sex 58% 60%BMC Pediatrics 2006, 6:20 http://www.biomedcentral.com/1471-2431/6/20
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Furthermore, the number of immunized infants with a
reduction in adverse cardiorespiratory events in the 72
hours post-immunization was statistically significantly
lower than in the control group at an equivalent chrono-
logic age, and an immunized infant was only 17% as
likely as a control infant to have a reduction in adverse
cardiorespiratory events. Comparing our adverse event
rate to those reported in the literature, one small prospec-
tive study found no change in the frequency of apnea or
increased oxygen requirements in 16 infants < 29 weeks
gestation receiving whole cell pertussis vaccine [11], while
other studies reported an incidence of adverse cardiorespi-
ratory events of only ~8% in infants receiving whole cell
pertussis vaccine [2,3]. Also using whole cell pertussis vac-
cine, a retrospective study of 97 infants [4] and a follow
up prospective study [5] by the same group found rates of
adverse cardiorespiratory events with incidences of 20%
and 17% respectively. Unexpectedly, higher incidences of
38 to 47% that are more comparable to the rate in the cur-
rent study have been documented in more recent studies
with acellular pertussis vaccines [8-10]. However, these
varying rates may be partially accounted for by differences
in the definition of cardiorespiratory events and in moni-
toring practices.
Despite the fact that the current study demonstrated an
increase in adverse cardiorespiratory events post-immuni-
zation, most of these events were clinically insignificant
and the number requiring treatment was not statistically
different between the immunized and control groups. As
described in the previous literature, most events resolved
spontaneously or required only brief stimulation or tran-
sient low flow oxygen [3-10]. Sixteen percent of the
immunized infants in the current study required increased
oxygen or CPAP, which fits with the wide range of 0–33%
reported in previous studies [3-10], while 16% required
increased theophylline doses and a single infant required
reintubation on the third day post-immunization. The
relationship of this event to the immunization is not clear.
The main reason for changing from whole cell to acellular
pertussis vaccine is the decreased reactogenicity of the lat-
ter vaccine. However, in the current study there was no
statistically significant difference in the frequency of
adverse cardiorespiratory events post-immunization with
whole cell as compared to acellular pertussis vaccines in
preterm infants. This differs from a previous study in pre-
term infants where increased adverse cardiorespiratory
events and increased systemic inflammatory markers (IL-
6, CRP) occurred in 30% of infants receiving whole cell
pertussis vaccine but in no infants receiving acellular per-
tussis vaccine [7].
Previous studies found that the risk of adverse cardiores-
piratory events post- immunization was higher in infants
with lower birth weight [6], lower current weight [6],
lower gestational age [4], or postnatal age < 70 days [10],
while other studies did not confirm these findings [5,7] or
found a correlation with the presence of adverse cardiores-
piratory events during the 24 hours preceding the immu-
nization [9]. In the current study, only the current weight
appeared to be a risk factor where the infant's likelihood
of having an adverse cardiorespiratory event decreased by
17% for every 100 gram increase in weight. Other poten-
tial risk factors such as chronic lung disease, duration of
ventilation or oxygen dependency were not addressed in
our study.
One limitation of our study is that patients not on elec-
tronic cardiorespiratory monitors 72 hours prior to and
post-immunization were excluded. These infants would
presumably be more stable and may be less likely to have
an adverse event precipitated by the immunization. There-
fore, the frequency of apnea or bradycardia in preterm
infants receiving their first DTP-IPV- Hib immunization
may have been over-estimated in the current study. The
study dates of the controls that corresponded to the
immunization date of the immunized infants were
adjusted up to 7 days in 55 patients to avoid confounding
Table 2: Incidence of adverse cardiorespiratory events in preterm infants in the 72 hours following first immunization with DTP-IPV-
Hib vaccine as compared to control infants.
Immunized infants (n = 
124)
Controls (n = 124) OR* 95% CI
Increase in adverse 
cardiorespiratory events
56 36 2.41 1.3,4.5
Resurgence of ABD 9 2 4.50 0.97,20.8
Increase in ABD 47 34 1.60 0.94,2.80
Reduction in adverse 
cardiorespiratory events
18 51 0.18 0.08,0.39
Resolution of ABD 6 4 1.7 0.40,6.90
Decrease in ABD 12 47 0.13 0.05,0.32
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factors, which could have affected results. It would have
been ideal but impractical to use a shorter window. Chart-
ing of adverse cardiorespiratory events by nursing staff can
vary and it is possible that nurses were more diligent
about observing infants who had recently received an
immunization. However, we suspect there was limited
awareness amongst nurses or physicians of the potential
for immunizations to precipitate adverse cardiorespira-
tory events, as many infants could not be included in the
study as they were not on a monitor post-immunization.
It has been suggested that when looking for adverse events
related to immunization, it may be inappropriate to use
unimmunized children as controls as they may differ in
important ways from immunized children [12]. However,
almost all control infants in the current study were already
immunized or were eventually immunized. Because
immunization is often arranged just prior to discharge, if
there was a systemic bias, it would be towards the immu-
nized infants being "more stable" than the control infants
and less likely to have adverse cardiorespiratory events at
this chronologic age.
Conclusion
More hospitalized preterm infants ≤ 32 weeks developed
an increase in adverse cardiorespiratory events after their
first immunization with DTP-IPV-Hib than did a control
group at an equivalent chronologic age. A lower weight at
the time of immunization was a risk factor for an increase
in adverse cardiorespiratory events. The risk of these
events does not appear to have been decreased by the use
of acellular pertussis vaccine. The majority of these events
were clinically insignificant and should not prompt delays
in immunization. However, whenever practical, immuni-
zation should be given at least 72 hours prior to planned
discharge in this fragile population to allow for cardiores-
piratory monitoring post-immunization.
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